Treatment Approved for “Undruggable” Lung Cancer

The FDA has approved sotorasib for the 13% of patients whose non –small cell lung cancer has the KRAS G12C variant that confers resistance to systemic therapy. Sotorasib is a small molecule that specifically inhibits the KRAS G12C protein, which leads to uncontrolled cell growth. It is indicated for adults whose cancer hasn’t responded to at least 1 type of s ystemic therapy.
Source: JAMA - Category: General Medicine Source Type: research